[Role of GP IIb/IIIa blockers in clinical cardiology].
Platelet aggregation and thrombosis play a key role in the pathogenesis of unstable coronary syndromes and their ischemic complication. The platelet glycoprotein (GP) IIb/IIIa receptor represents the final common pathway leading to platelet aggregation. In the last 10 years agents that block the GP IIb/IIIa receptor has been developed and tested on a large number of large-scale, randomized trials showing that these drugs, particularly when administered in intravenous form, reduce morbidity and death in patients with acute coronary syndromes and those undergoing percutaneous intervention.
Rossi
Marco L
ML
Merlini
Piera Angelica
PA
D000077284:Abciximab; D000789:Angina, Unstable / Q000188:drug therapy; D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use*; D003327:Coronary Disease / Q000517:prevention & control*; D000077542:Eptifibatide; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000494:pharmacology / Q000627:therapeutic use*; D009203:Myocardial Infarction / Q000188:drug therapy; D010455:Peptides / Q000494:pharmacology / Q000627:therapeutic use*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors*; D000077466:Tirofiban; D014443:Tyrosine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use*
D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D010455:Peptides; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D014443:Tyrosine; D000077466:Tirofiban; D000077542:Eptifibatide; D000077284:Abciximab